Video

Belimumab With Standard Therapy Proves Beneficial in Lupus Nephritis

In today’s one-on-one interview, we talk with Dr. Richard Furie who is chief of rheumatology at Northwell Health in New York. Dr. Furie is the lead investigator of a study on lupus nephritis just published in the New England Journal of Medicine. Dr. Furie and colleagues from the Feinstein Institutes for Medical Research reported that belimumab with standard therapy has been shown to be an effective treatment for lupus nephritis. If the treatment is approved by the U.S. Food and Drug Administration, it would be the first of its kind for this condition. In this presentation, Dr. Furie tell us more.

CITATION: Richard Furie, M.D., Brad H. Rovin, M.D., Frédéric Houssiau, M.D., Ph.D., et al. "Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis," New England Journal of Medicine. Sept. 17, 2020. DOI: 10.1056/NEJMoa2001180

Related Videos
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
Considering Viral Infections in Patients With Rheumatic Disease With Leonard Calabrese, DO
Leonard H. Calabrese, DO, Professor of Medicine and Vice Chair, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University
Alvin Wells, MD, PhD: Making Informed Treatment Decisions With New Testing Strategies
Alvin Wells, MD, PhD
Upcoming Research in PsA, AxSpa, with Philip Mease, MD
Philip Mease, MD, Clinical Professor, University of Washington School of Medicine and Director, Rheumatology Research, Swedish Medical Center
Related Content
Radiomics Model Distinguishes Gout Flares, May Improve Clinical Decision Making
October 10th 2024

Radiomics Model Distinguishes Gout Flares, May Improve Clinical Decision Making

Victoria Johnson
Emerging Agents in the Treatment of Rheumatic Diseases
October 2nd 2023

Emerging Agents in the Treatment of Rheumatic Diseases

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR Philip J. Mease, MD
Ixekizumab as Effective, if not More Effective as TNFi, JAKi, IL-12/23i for PsA Treatment
October 8th 2024

Ixekizumab as Effective, if not More Effective as TNFi, JAKi, IL-12/23i for PsA Treatment

Victoria Johnson
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
August 31st 2023

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR John B. Boone, MD, FACR Madelaine Feldman MD, FACR
David Stapor, MD | Credit: Allegheny Health Network
October 4th 2024

Allegheny Health Network: A Pioneer in the Prevention and Care of Osteoporosis

Allegheny Health Network
Credit: Allegheny Health Network
October 4th 2024

Unlocking the Mystery at AHN Autoimmunity Institute

Allegheny Health Network
© 2024 MJH Life Sciences

All rights reserved.